EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:750075 - briakinumab
| ChEBI ID | CHEBI:750075 |
| ChEBI Name | briakinumab |
| Stars | |
| Last Modified | 29 June 2026 |
| Submitter | chembl-etl |
| Roles Classification |
|---|
| Biological Role: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. |
| Applications: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antipsoriatic A drug used to treat psoriasis. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| briakinumab (CHEBI:750075) has role antipsoriatic (CHEBI:50748) |
| briakinumab (CHEBI:750075) has role immunosuppressive agent (CHEBI:35705) |
| briakinumab (CHEBI:750075) is a organic molecular entity (CHEBI:50860) |
| Synonyms | Source |
|---|---|
| A-796874.0 | ChEMBL |
| ABT-874 | ChEMBL |
| Briakinumab | ChEMBL |
| BSF 415977 | ChEMBL |
| BSF-415977 | ChEMBL |
| J-695 | ChEMBL |
| Brand Name | Source |
|---|---|
| Ozespa | ChEMBL |